If you look at the latest annual financial, total expenditure cost was $50M with a net loss of $24M ($12M directly from ADAPT segment), nearly half of the expenditure was due to employee salary of $23.5M, $3.5M are directors salaries with the other employee averaging $200K (this was $150K the previous year) and well over the Australia's average salary of $80K.
This is why their cash burn has been so high.......you wouldn't mind getting a job there and earning well over 2x the average salary.
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-142
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
-0.500(3.19%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.75 | $15.75 | $15.00 | $294.3K | 19.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1135 | $15.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.35 | 88 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |